Business Of Biotech

Hosted by Ben Comer

Business Management ScienceInterviews guests

Website RSS feed LinkedIn

Episodes

319

Latest episode

Aug 2026

Language

About the show

The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, regulatory, and commercial challenges you’ll face as you navigate your company from an idea to success in the clinic and beyond. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is produced by Life Science Connect.

Listen to episodes

60 recent

August 17, 2026Episode 31950 min

Getting To A First Product Approval With Celcuity's Brian Sullivan

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Brian Sullivan, CEO at Celcuity, talks about winning the company's first FDA approval for Revtorpyk, a kinase inhibitor for breast cancer patients, and why targeting an “untreated disease mechanism” can beat chasing a single mutation. Brian also discusses the process for licensing a shelved Pfizer asset for development, designing Phase 3 trials that challenge assumptions, the benefits of FDA's Real-Time Oncology Review, and managing downside risk while advancing new indications, all while building a launch-ready company without losing pipeline momentum. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter . Get in touch with guest and topic suggestions : ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn : https://www.linkedin.com/in/bencomer/

August 10, 2026Episode 31850 min

Cell Therapy Advances And Biotech Leadership With Nkarta's Paul Hastings

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Paul Hastings, Founding CEO and Board Member at Nkarta, an allogeneic cell therapy developer, talks about building off-the-shelf CAR NK cell therapies for autoimmune disease. Paul is candid about problems with clinical trial infrastructure in the U.S., what it will take to fix trial access (biotechs should actively facilitate patient access to trials and work with community health centers to establish new trial sites), and why biotech leaders have a responsibility to speak up about federal policies shaping the life sciences innovation ecosystem. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter . Get in touch with guest and topic suggestions : ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn : https://www.linkedin.com/in/bencomer/

August 3, 2026Episode 31755 min

A Rescue Model For Shelved Drug Candidates With Annette Bakker, Ph.D. And Andrew Lo, Ph.D.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Annette Bakker, Ph.D., CEO at the Children's Tumor Foundation, and Andrew Lo, Ph.D., Finance Professor at MIT's Sloan School of Management and Director of the Laboratory for Financial Engineering, talk about the methods and economics for turning abandoned drug candidates into new therapies for patients. Annette and Andrew share the story of Gomekli, a formerly shelved Pfizer drug candidate spun out into SpringWorks Therapeutics, and approved in 2025 for NF Type 1 tumors (Merck KGaA subsequently acquired SpringWorks for $3.9 billion). They also detail plans for bringing more shelved candidates back into development, using a shared data infrastructure and a matchmaking tool to pair interested drug developers with investors and funding. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter . Get in touch with guest and topic suggestions : ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn : https://www.linkedin.com/in/bencomer/

July 27, 2026Episode 31654 min

Using Genetics To Discover New Treatments With Regeneron Genetics Center's Aris Baras, M.D.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Aris Baras, M.D., SVP, Head of Regeneron Genetics Center (RGC) and Co-Head of Regeneron Genetic Medicines, talks about using large-scale human genetics to find better drug targets based on "superhuman" variants. Aris explains how multi-omics, linked health records, and AI are helping developers move faster in the clinic and reduce the odds of failure, while also pushing biotech toward earlier disease prediction and more preventive care. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter . Get in touch with guest and topic suggestions : ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn : https://www.linkedin.com/in/bencomer/

July 20, 2026Episode 31556 min

Late-Stage Development And Commercial Planning With CervoMed's Matt Winton, Ph.D.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Matt Winton, Ph.D., Chief Commercial and Business Officer at CervoMed, talks about preparing for the late-stage development of neflamapimod in dementia with Lewy bodies (DLB) and commercial planning for an anticipated launch. Winton talks about CMC and manufacturing scale-up, partnership, communicating with regulators and the benefits of global regulatory alignment on protocols for the Phase 3 trial. He also talks about building value through HEOR and payer engagement in parallel with clinical development, and pricing in the context of policy changes and shifting global launch dynamics. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter . Get in touch with guest and topic suggestions : ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn : https://www.linkedin.com/in/bencomer/

July 13, 2026Episode 31448 min

BoB@BIO: Biotech In The Balance With Ovid Therapeutics' Dr. Jeremy Levin

We love to hear from our listeners. Send us a message. On the Business of Biotech this week, industry veteran Dr. Jeremy Levin, Founder, Chairman, and former CEO at Ovid Therapeutics, sits down alongside the 2026 BIO Convention to talk about why public distrust and politicized institutions are putting the scientific enterprise at risk. We dig into what biotech leaders owe patients and the public, how innovation and capital can migrate out of the U.S., and what it takes to build biotech companies that last. Dr. Levin talks about his recently published book, Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust, what he learned during the writing process, and offers advice for first-time biotech CEOs. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter . Get in touch with guest and topic suggestions : ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn : https://www.linkedin.com/in/bencomer/

July 6, 2026Episode 31339 min

BoB@BIO: Biotech Investing And Deals With Sofinnova's Maha Radhakrishnan, M.D.

We love to hear from our listeners. Send us a message. This week's episode of the Business of Biotech was recorded at the BIO Convention in San Diego, where guest Maha Radhakrishnan, M.D., Executive Partner, Private Equity, at Sofinnova, spoke about her move from big pharma and biotech to private equity investing, and what makes a late-stage asset deal work. Maha also talks about how China-originated programs are changing development timelines, and where the next wave of CNS and metabolic innovation could come from. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter . Get in touch with guest and topic suggestions : ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn : https://www.linkedin.com/in/bencomer/

June 29, 2026Episode 31248 min

Targeting Tau in Alzheimer's Disease With Voyager Therapeutics' Al Sandrock, M.D., Ph.D.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Al Sandrock, M.D., Ph.D., President and CEO at Voyager Therapeutics, talks about why tau is becoming a central target in Alzheimer’s drug development and how gene therapy delivery across the blood-brain barrier could change what treatment looks like at scale. Sandrock shares his current thinking on the amyloid vs. beta debate (it's likely both) in Alzheimer's disease treatment, the role of emerging tools like fluid biomarkers in diagnosis and prevention, and why small biotechs take bigger risks than big pharma. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter . Get in touch with guest and topic suggestions : ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn : https://www.linkedin.com/in/bencomer/

June 22, 2026Episode 31155 min

Keeping An Early-Stage Cell Therapy Biotech In The Black With IN8bio's William Ho

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, William Ho, CEO of IN8bio, explains why gamma delta T cells may have an edge against cancer, including solid tumors like glioblastoma. He also offers up a candid and step-by-step look at what it takes to finance an early clinical-stage cell therapy company through a punishing IPO market and a long cash crunch. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter . Get in touch with guest and topic suggestions : ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn : https://www.linkedin.com/in/bencomer/

June 15, 2026Episode 31055 min

Drug Launch Success In A Changing Commercial Landscape With ACMA's William Soliman, Ph.D.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, William Soliman, Founder and CEO of the Accreditation Council for Medical Affairs (ACMA), and Founder and CIO of White Manna Capital Partners, talks about why biotech drug launches so often miss expectations, and how to build an integrated commercialization plan that holds up with physicians, patients, and payers. William also describes the evolution in medical affairs, why standards and certification matter, and how AI and new media channels are reshaping how drug information reaches patients and prescribers. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter . Get in touch with guest and topic suggestions : ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn : https://www.linkedin.com/in/bencomer/

Is this your show?

Claim this listing to keep it up to date, reach guests who want to pitch you, and manage bookings with Guestify.

Claim this listing

More Business podcasts

Rebel's Edge with Jon & Pete Najarian

Market Rebellion

BusinessMarketing

Media Roundtable

PodcastOne

BusinessMarketingInterviews guests

Real Talk Rentals

On Q Property Management

Business